Enlivex Therapeutics

Oren Hershkovitz, Ph.D., CEO of Enlivex Therapeutics Ltd. (NASDAQ: ENLV) was recently a guest on Benzinga’s All-Access. Enlivex is a clinical-stage biotechnology company focused on macrophage reprogramming that intends to develop and commercialize a drug pipeline for macrophage reprogramming...

This month, H.C. Wainwright & Co. reiterated its buy rating for Enlivex Therapeutics Ltd. (NASDAQ: ENLV) with a 12-month price target of $15 per share, based on a valuation estimated at $320 million. Despite forecasting a net loss of $1.75 per share in 2023 largely due to high R&D spend,...

This month, Enlivex Therapeutics Ltd. (NASDAQ: ENLV) announced a new clinical collaboration agreement with Beigene Ltd (NASDAQ: BGNE) to test a new combination treatment to fight advanced-stage solid tumors. The therapy will combine Allocetra, Enlivex’s novel macrophage reprogramming...

Enlivex Therapeutics Ltd. (NASDAQ: ENLV) announced that the U.S. Food & Drug Administration (FDA) had cleared an  Investigational New Drug (IND) application to study Allocetra™ in patients with advanced solid malignancies. The FDA’s Phase I/II clearance follows a recent...

On November 13, Enlivex (NASDAQ: ENLV) announced that the first patient has been dosed in its Phase I/II clinical trial of Allocetra. The novel off-the-shelf cell therapy is designed to help break through the immune-suppressing tumor microenvironment – a key roadblock rendering potent...

Enlivex Therapeutics Ltd. (NASDAQ: ENLV) announced that the first patient has been dosed in Phase I/II clinical trial designed to evaluate the safety, tolerability and preliminary efficacy of Allocetra™ alone, and in combination with a PD1 checkpoint inhibitor, in patients with advanced solid...

Sign up for this week’s All Access giveaway here!  Oren Hershkovitz, Ph.D., CEO of Enlivex Therapeutics Ltd. (NASDAQ: ENLV), was a guest on Benzinga’s All Access on November 11, 2022. Enlivex creates novel therapeutics for serious diseases like cancer, primarily through a process...

Enlivex Therapeutics Ltd. (NASDAQ: ENLV) announced that Israel, Spain and Greece have cleared amendments to the company’s Phase II trial protocol that will allow the study to enroll more patients.  The cleared amendments also allow Enlivex to use a newly developed frozen formulation of...

Since Robert Hooke discovered cells in 1665 and Theodor Schwann proposed the classical cell theory in 1839, the cell therapy industry has grown by leaps and bounds. Today, there are several potential applications of cell therapies. They can be used in treating infectious and...

The Israeli Ministry of Health (MOH) approved a Phase I/II trial of Enlivex Therapeutics Ltd.’s (NASDAQ: ENLV) proprietary immunotherapy drug-candidate AllocetraTM.  AllocetraTM is a cell therapy that uses healthy donor cells to reprogram and strengthen the patient’s immune...

Cancer research has come a long way in the past few decades, pioneering treatments like chemotherapy and radiation treatments that have become essential weapons in the fight against this deadly and difficult to treat disease. Even so, many cancers don’t respond to the current standard of care...

One of the chief challenges cancer researchers face today is finding a way to outsmart the disease’s defense mechanisms. Because the cancer isn’t an infection but a mutation of the patient’s own cells, it has a unique ability to evade attack from the immune system, both by hiding...

Shai Novik, Executive Chairman of the Board at Enlivex Therapeutics, Ltd. (NASDAQ: ENLV), was a guest speaker at Benzinga’s All Access on June 17th, 2022.  Enlivex Therapeutics is a clinical stage, macrophage reprogramming immunotherapy company developing Allocetra - an off-the-shelf...